Home » Blog » Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis
7 Views
SaveSavedRemoved 0
Lebrikizumab remedy in moderate-to-severe atopic dermatitis (AD) improved patient-reported outcomes within the phase-3 trials ADvocate1&2 (monotherapy) by means of 52 weeks and ADhere (mixture topical corticosteroids) by means of 16 weeks. We report the influence of lebrikizumab on AD indicators/signs as reported by the Affected person-Oriented Eczema Measure (POEM) at week 104 of steady remedy in ADjoin, a long-term extension.
Trending Merchandise
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$25.00
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$29.71
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$32.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$13.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$17.99
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$7.85
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$8.83
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$45.40
Added to wishlistRemoved from wishlist 0
Added to wishlistRemoved from wishlist 0
$9.99
Added to wishlistRemoved from wishlist 0
Carlyle Cat’s Claw Capsules 1000mg | 180 Count | Uncaria Tomentosa | Non-GMO, Gluten Free Supplement
Added to wishlistRemoved from wishlist 0
$15.28